Although checkpoint blockade immunotherapy has played a significant role in improving the OS of lung cancer patients, the objective response rate of single immunotherapy was only approximately 20% in lung cancer patients; therefore, single immunotherapy was not recommended in lung cancer patients with PD-L1<50% (13, 14). The gene discussed is CD274; the disease is lung carcinoma.